Theravance Biopharma TBPH Free cash flow margin

Free cash flow margin at other companies

Gyre Therapeutics, Inc.GYRE

-5.1%—

LQD

Liquidia CorporationLQDA

-150.7%-64.4pp

United TherapeuticsUTHR

34.6%-0.1pp

Zevra Therapeutics, Inc.ZVRA

-75%-30.5pp

Mirum Pharmaceuticals, Inc.MIRM

-37%—

Pulmonx CorporationLUNG

-33.2%-4.4pp

FAQ

What is Theravance Biopharma's free cash flow margin?

Theravance Biopharma (TBPH) reported free cash flow margin of 221.9% in Q4 2025.

How has Theravance Biopharma's free cash flow margin changed year-over-year?

Theravance Biopharma's free cash flow margin increased by 1304.0% year-over-year, from -18.4% to 221.9%.

What is the long-term trend for Theravance Biopharma's free cash flow margin?

Over 5 years (2020 to 2025), Theravance Biopharma's free cash flow margin has grown at a -9.1% compound annual growth rate (CAGR), from -357.7% to 221.9%.

What does free cash flow margin mean?

Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.